MSParis2017: Clinical Update of Emerging S1P Therapeutics for the Treatment of Multiple Sclerosis

http://academiccme.com/wp-content/uploads/2017/12/iStock-538262387-wpcf_400x400.jpg

Course Information

Therapautic Area: Neurology
Format(s): Webcast, Post Conference Review and Analysis
Credit(s): 1.00 AMA PRA Category 1 Credit(s)™
Activity Dates: December 6, 2017 to December 5, 2018

 

Program Overview

This CME post conference review and analysis will feature content presented at the MS Paris 2017 7th Joint ECTRIMS-ACTRIMS Meeting in Paris, France. Four expert faculty will discuss the role of S1P therapeutics in the management of patients with multiple sclerosis. An analysis of recent efficacy and safety data of S1P based therapeutics will be reviewed. The faculty will also discuss how to apply the S1P based therapeutics in order to optimally manage disease activity. Upon completion of this activity, learners will gain a better understanding of S1P therapeutics for the treatment of multiple sclerosis, ultimately improving patient outcomes.

Target Audience

Neurologist, primary care physicians, internists and advanced practice providers, including NPs and PAs, responsible for the diagnosis, treatment or management of patients with multiple sclerosis.

Learning Objectives

1. Examine the role of S1P therapeutics in the management of patients with MS.
2. Analyze recent efficacy and safety data of S1P based therapeutics for the treatment of  MS as presented at the Joint ECTRIMS-ACTRIMS Meeting.
3. Apply S1P based therapeutics to optimally manage disease activity in MS.
4. Utilize the health care team and shared decision making to achieve improved outcomes.

Faculty

 

Markowitz Headshot copyClyde Markowitz, MD
Director, MS Center
Associate Professor, Department of Neurology
University of Pennsylvania, Perelman School of Medicine
Philadelphia, PA

 

 

Screen Shot 2017-12-06 at 9.13.46 AMPatricia Coyle, MD
Professor and Vice Chair (Clinical Affairs)
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

 

 

 

Fox copy

Edward J. Fox, MD, PhD, FAAN
Director, Multiple Sclerosis Clinic of Central Texas
Clinical Associate Professor
University of Texas Medical Branch
Round Rock, TX

 

 

 

Freedmand headshot copyMark S. Freedman, MD
Professor of Medicine
University of Ottawa
Senior Scientist, Ottawa Hospital Research Institute
Ottawa, Ontario, Canada

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

 

Faculty Relationship Identified With:
Clyde Markowitz, MD Consultant/Advisor: Bayer AG; Biogen; EMD Serono, Inc; Genetech Inc.; Genzyme Corporation; Novartis AG; Opexa Therapeutics, Inc.; F. Hoffmann-La Roch Ltd.; Teva Pharmaceutical Industries Ltd.
Patricia Coyle, MD Consultant/Advisor: AbbVie Inc.; Accordant, A CVS Caremark Company; Acorda Therapeutics; Bayer AG; Biogen; Celgene Corporation; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Novartis AG; Sanofi Genzyme; EMD Serono, Inc.; Teva Pharmaceutical Industries Ltd.Grant/Research Support: Actelion Pharmaceuticals Ltd; Alkermes; F. Hoffmann-La Roche Ltd; Genentech, Inc.; MedDay; National Institute of Neurological Disorders and Stroke; Novartis AG
Edward Fox, MD Consultant/Advisor: Acorda Therapeutics; Bayer AG; Biogen; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Novartis AG; Sanofi Genzyme; Teva Pharmaceutical Industries Ltd.Grant/Research Support: Acorda Therapeutics; Biogen; Celgene Corporation; Chugai Pharmaceutical Co., Ltd.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Mallinckrodt; MedDay; Novartis AG; Sanofi Genzyme; TG Therapeutics, Inc.Speaker’s Bureau: Acorda Therapeutics; Biogen; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Novartis AG; Sanofi Genzyme; Teva Pharmaceutical Industries Ltd.
Mark Freedman, MD Consultant/Advisor: Actelion Pharmaceuticals Ltd.; Bayer AG; Biogen; Chugai Pharmaceutical Co., Ltd.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genzyme Corporation; MedDay; Merck & Co., Inc.; Novartis AG; sanofi-aventis U.S. LLC; Teva Canada InnovationGrant/Research Support: Genzyme Corporation Speaker’s Bureau: Genzyme Corporation

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski; Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by independent educational grants from Actelion Pharmaceuticals Ltd. and Celgene Corporation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Actelion Pharmaceuticals Ltd. and Celgene Corporation do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact admin@academiccme.com.
BUTTON


Provided by AcademicCME-web